GlobeNewswire·Nov 5, 2026, 4:05 PM ET

Mobia Medical Reports Third Quarter 2026 Financial Results

Mobia Medical, Inc. reported third quarter 2026 revenue of $15.6 million, representing 73% growth over the prior year period.
The company achieved a gross margin of 83.2% for the quarter, driven by lower freight, tariff costs, and reduced inventory write-offs.
Average active territories increased to 40 during the quarter, up from 22.5 in the same period last year.
Full year 2026 revenue guidance was raised to a range of $57.0 million to $57.5 million, up from the previous range of $54.0 million to $56.0 million.
Operating expenses increased 71% to $31.5 million due to higher personnel costs, increased sales commissions, and $2.2 million in additional stock-based compensation.
The company reported a net loss of $17.3 million, or $0.52 per share, compared to a net loss of $11.4 million, or $13.31 per share, in the prior year period.
As of September 30, 2026, cash and cash equivalents totaled $160.7 million.
The updated 2026 AHA Guideline for stroke recovery now includes paired VNS, validating the company's Vivistim Paired VNS Therapy.
Total revenue for the first nine months of 2026 reached $41.2 million, compared to $21.3 million in the same period of 2025.
The company's IPO resulted in a significant increase in weighted-average common shares outstanding, contributing to the improved net loss per share figure.